TD Ameritrade Investment Management’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-395
Closed -$37K 153
2023
Q2
$37K Buy
395
+384
+3,491% +$33.4K ﹤0.01% 260
2023
Q1
$1K Hold
11
﹤0.01% 544
2022
Q4
$1K Sell
11
-35
-76% -$2.7K ﹤0.01% 544
2022
Q3
$4K Sell
46
-31
-40% -$2.98K ﹤0.01% 440
2022
Q2
$7K Sell
77
-5
-6% -$518 ﹤0.01% 448
2022
Q1
$10K Buy
82
+4
+5% +$449 ﹤0.01% 500
2021
Q4
$10K Buy
78
+55
+239% +$6.42K ﹤0.01% 485
2021
Q3
$2K Sell
23
-20
-47% -$2.28K ﹤0.01% 579
2021
Q2
$4K Buy
43
+23
+115% +$2.17K ﹤0.01% 542
2021
Q1
$2K Hold
20
﹤0.01% 583
2020
Q4
$2K Sell
20
-3
-13% -$249 ﹤0.01% 583
2020
Q3
$2K Hold
23
﹤0.01% 579
2020
Q2
$2K Sell
23
-4
-15% -$284 ﹤0.01% 568
2020
Q1
$2K Sell
27
-3
-10% -$216 ﹤0.01% 541
2019
Q4
$2K Buy
30
+27
+900% +$2.11K ﹤0.01% 569
2019
Q3
$0 Buy
+3
New +$211 ﹤0.01% 652
2019
Q2
Sell
-465
Closed -$30K 651
2019
Q1
$30K Buy
+465
New +$26.5K ﹤0.01% 285

Other funds holding EW

TD Ameritrade Investment Management's EW Position: Q3 2023 in Review

TD Ameritrade Investment Management sold out of Edwards Lifesciences (EW) in Q3 2023, closing a stake of 395 shares — an estimated $37K sold.

TD Ameritrade Investment Management first reported a position in EW in Q1 2019 and held it in 17 quarters. The position peaked at $37K in Q2 2023. 1,219 funds tracked by Wall St. Rank hold EW as of Q3 2023.

  • TD Ameritrade Investment Management reported no remaining Edwards Lifesciences position as of Q3 2023 after selling out during the quarter.
  • TD Ameritrade Investment Management sold 395 Edwards Lifesciences shares in Q3 2023, an estimated $37K.
  • TD Ameritrade Investment Management first reported a position in Edwards Lifesciences in Q1 2019 and held it in 17 quarters.
  • TD Ameritrade Investment Management's Edwards Lifesciences position peaked at $37K in Q2 2023.
  • 1,219 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2023.

Based on TD Ameritrade Investment Management's 13F filing for Q3 2023.